This article is part of the supplement: Proceedings of the Second Workshop of the Regional Study Group on HCV in the Calabria Region (Southern Italy). The virus-host-therapy pathway in HCV disease management: from bench to bedside in the era of Directly Acting Antivirals
Molecular diagnostic and predictive tests in the evolution of chronic hepatitis C anti-viral therapies
Roche Diagnostics, GCS, CH 6343 Rotkreuz, Switzerland
BMC Infectious Diseases 2012, 12(Suppl 2):S8 doi:10.1186/1471-2334-12-S2-S8Published: 12 November 2012
Since the discovery of HCV, polymerase chain reaction (PCR) has significantly contributed to the understanding of the virus life cycle and its replicative kinetics during anti-viral therapy. Parallel to the progression of dual and triple combination treatment, real-time PCR molecular tests have constantly improved in their ability to monitor viral load and drive personalized management schedules. The current sensitivity, accuracy and dynamic range of the available assays fulfil the requirement of “companion diagnostics” and support the development of new directly acting antiviral (DAA)-based regimens.